Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Average Rating of “Moderate Buy” from Analysts

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has been assigned a consensus rating of “Moderate Buy” from the fourteen analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $80.2308.

RARE has been the subject of a number of analyst reports. Truist Financial lowered their target price on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. TD Cowen decreased their price target on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a report on Wednesday, October 8th. Canaccord Genuity Group cut their target price on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Finally, Barclays decreased their target price on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, November 24th.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 7,942 shares of the stock in a transaction on Monday, October 13th. The shares were sold at an average price of $31.51, for a total value of $250,252.42. Following the transaction, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at $3,095,132.77. This trade represents a 7.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Karah Herdman Parschauer sold 2,450 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, September 12th. The stock was sold at an average price of $31.17, for a total transaction of $76,366.50. Following the sale, the executive vice president owned 73,271 shares in the company, valued at $2,283,857.07. This represents a 3.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 10,456 shares of company stock valued at $328,486. Company insiders own 5.50% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. increased its position in Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after buying an additional 1,864,164 shares during the period. Norges Bank purchased a new position in shares of Ultragenyx Pharmaceutical during the second quarter worth approximately $35,765,000. Adage Capital Partners GP L.L.C. grew its position in shares of Ultragenyx Pharmaceutical by 81.6% during the first quarter. Adage Capital Partners GP L.L.C. now owns 2,149,000 shares of the biopharmaceutical company’s stock worth $77,815,000 after acquiring an additional 965,919 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Ultragenyx Pharmaceutical by 439.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,163,755 shares of the biopharmaceutical company’s stock valued at $42,314,000 after acquiring an additional 947,865 shares during the period. Finally, Vestal Point Capital LP purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter valued at $22,560,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Stock Performance

RARE stock opened at $36.54 on Friday. The company’s 50 day moving average price is $32.74 and its 200 day moving average price is $32.42. The firm has a market capitalization of $3.53 billion, a price-to-earnings ratio of -6.15 and a beta of 0.16. Ultragenyx Pharmaceutical has a fifty-two week low of $25.81 and a fifty-two week high of $50.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The firm had revenue of $159.93 million during the quarter, compared to analysts’ expectations of $167.42 million. During the same quarter in the prior year, the firm earned ($1.40) EPS. The firm’s revenue was up 14.6% compared to the same quarter last year. Equities analysts forecast that Ultragenyx Pharmaceutical will post -5.18 EPS for the current fiscal year.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.